Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Air India Partners with Volantio to Enhance Passenger Experience
-
IREN Delivers Horizon 1 to Microsoft and Achieves NVIDIA Exemplar Cloud Status on GB300 NVL72
-
AFC Announces Financial Results for the Second Quarter 2026
-
Goldera Provides Update on Settlement Agreement and Investment in Gold Orogen
-
Intuitive Machines Reports Second Quarter 2026 Financial Results; Continues Record Backlog Expansion With Quarter-end Backlog of $1.8 Billion
-
SalesCloser Granted Third U.S. Patent, Protecting In-Conversation AI Appointment Booking
-
Rio2 Reports Q2 2026 Financial and Operating Results and Webinar
-
Ascendis Pharma Reports Second Quarter 2026 Financial Results
-
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
-
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
-
GDS Holdings Limited Reports Second Quarter 2026 Results
-
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
-
Indonesia Energy Corporation Reports Progress on Drilling of K-29 Well
-
FitLife Brands Announces Second Quarter 2026 Results
-
Collegium Announces $50 Million Accelerated Share Repurchase Program
-
Creative Realities Reports Fiscal 2026 Second Quarter Results
-
Reborn Coffee Signs $20 Million Annual Supply Agreement with The Mighty Oak, Strengthening Its Revenue Base and Profitability Through the Conversion of Existing Supply Volume
-
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
-
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
-
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
-
UTStarcom Announces Finance Leadership Changes
-
PO Wealth Sharing Group Surpasses 200,000 Users Across 22 Countries
-
Caliber Goes Live with PURE Pickleball & Padel Tokenized Real Estate Investment Offering
-
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
-
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
-
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
-
Calian Reports Record Results for the Third Quarter of Fiscal 2026
-
POET Technologies Reports Second Quarter 2026 Results: Revenue Up 112% Year-Over-Year in Sixth Consecutive Quarter of Sequential Growth
-
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
-
UNISYNC Corp. Reports Strong Q3 Fiscal 2026 Results with Improved Margins and Adjusted EBITDA
-
NexGold Reports Q2 2026 Financial and Operating Results
-
Victoria’s Secret & Co. Invites You to Listen to the Second Quarter 2026 Earnings Call
-
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
-
Palomino Laboratories to Participate in the 7th Annual Needham Virtual Semiconductor & SemiCap Conference on August 20, 2026
-
Stallion Uranium Intersects Highest Radioactivity to Date at Coyote, Plans to Expand Drill Program to 6,750 Metres
-
NexLiving Communities Reports Q2 2026 Results and Declares Quarterly Dividend
-
Amplify ETFs Files for Amplify S&P 500 Buffered Autocallable Yield Opportunity ETF (YO)
-
Lantronix to Report Fiscal 2026 Fourth Quarter Results on Aug. 26, 2026
-
Aebi Schmidt Group Reports 22% Increase in Adjusted EBITDA, 16% Growth in Order Intake and 9% Increase in Net Sales, Reflecting Strong Order Momentum and Over-Proportional Profitability Improvement
-
Xali Gold Advances Permitting and Contractor Selection for Drilling at Pico Machay
-
Restaurants Canada Announces 2026 Awards of Excellence Winners
-
Photys Therapeutics and Polymed Biopharmaceuticals Announce the Initiation of a Phase I Clinical Trial of PHT-776/HPB-143, an Oral IRAK4 PROTAC Degrader
-
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
-
Xanadu and University of Alberta Partner to Accelerate Pharmaceutical Discoveries with Quantum Computing
-
American Shared Hospital Services Reports Second Quarter and First Half 2026 Financial Results
-
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
Rocket Lab Corporation Announces Dollar-for-Dollar Replacement At-The-Market Equity Program
-
Rocket Lab Corporation Announces Progress on Iridium Acquisition: HSR Period Lapses; Form S-4 Filed; FCC Applications Filed; Capital Strategy Underway
-
YXT.com Reports Unaudited Financial Results for the First Six Months of 2026
